InflaRx NV
IFRXBuild a strategy around IFRX
InflaRx NV AI Insights
Informational only. Not investment advice.Snapshot
- Cash burn of 42.5M TTM against 6.4M cash on hand implies ~2 months runway without financing[Free Cash Flow TTM]
- R&D spend of 27.4M TTM is 435x revenue (63K) - pure clinical-stage biotech with no commercial traction[Research and Development TTM]
- Gross profit collapsed 88% YoY to -5.2M - cost structure inverted with COGS 83x revenue[Gross Profit 1Y Growth]
Watch Triggers
- Cash and Equivalents: Falls below 3M or financing announced — Sub-3M cash triggers going concern risk; financing terms reveal dilution severity
- Issuance of Capital Stock: Any new issuance above 10M — Signals survival mode - watch pricing vs current 68M market cap for dilution impact
- Research and Development TTM: Drops below 20M quarterly run rate — R&D cuts signal pipeline deprioritization or cash preservation mode
Bull Case
Clean balance sheet with 0.02 debt/equity and 45.4M equity provides collateral for non-dilutive financing or partnership leverage
P/B of 1.5x near tangible book (45.3M) offers downside protection if pipeline has any residual value
Bear Case
Cash runway under 3 months at current burn rate creates existential financing risk with severe dilution likely
Revenue of 63K TTM with -718% operating margin shows zero commercial viability - pure binary bet on clinical outcomes
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage IFRX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Imminent dilution or partnership required within 6 months to fund operations
- Cash of 6.4M vs 42.5M annual burn rate
- Zero capital stock issuance TTM despite losses
- Working capital of 44.4M mostly non-cash assets
Valuation Context
Caveats
IFRX Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$130.85M | — | ||
$116.68M | — | ||
0.00 | — | ||
$29,331 | -77.4% | — | |
$-0.63 | — | ||
-144,761% | -103509.5% | — | |
-146,304% | -111837.2% | — | |
$-28.81M | — | ||
-79.9% | -25.8% | — | |
Beta 5Y (Monthly) | unknown | — |
IFRX Dividend History
IFRX Stock Splits
IFRX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
05/06/26 | 03/31/26 | 6-K | |
03/20/26 | 12/31/25 | 20-F | |
11/10/25 | 09/30/25 | 6-K | |
08/07/25 | 06/30/25 | 6-K | |
05/07/25 | 03/31/25 | 6-K | |
03/20/25 | 12/31/24 | Unknown | |
11/08/24 | 09/30/24 | 6-K | |
08/08/24 | 06/30/24 | 6-K | |
05/08/24 | 03/31/24 | 6-K | |
03/21/24 | 12/31/23 | 20-F | |
03/20/25 | 12/31/23 | 20-F | |
11/01/23 | 09/30/23 | 6-K | |
08/10/23 | 06/30/23 | 6-K | |
05/11/23 | 03/31/23 | 6-K | |
03/22/23 | 12/31/22 | 20-F | |
11/09/22 | 09/30/22 | 6-K | |
08/05/22 | 06/30/22 | 6-K | |
05/12/22 | 03/31/22 | 6-K | |
03/24/22 | 12/31/21 | 20-F | |
11/05/21 | 09/30/21 | 6-K | |
08/05/21 | 06/30/21 | 6-K | |
05/12/21 | 03/31/21 | 6-K | |
03/25/21 | 12/31/20 | 20-F | |
10/29/20 | 09/30/20 | 6-K | |
07/30/20 | 06/30/20 | 6-K | |
05/21/20 | 03/31/20 | 6-K | |
04/29/20 | 12/31/19 | 20-F | |
11/07/19 | 09/30/19 | 6-K | |
08/14/19 | 06/30/19 | 6-K | |
05/23/19 | 03/31/19 | 6-K | |
03/28/19 | 12/31/18 | 20-F | |
11/21/18 | 09/30/18 | 6-K | |
08/09/18 | 06/30/18 | 6-K | |
05/17/18 | 03/31/18 | 6-K | |
03/29/18 | 12/31/17 | 20-F | |
12/21/17 | 09/30/17 | 6-K | |
11/08/17 | 06/30/17 | 424B4 | |
05/17/18 | 03/31/17 | 6-K | |
11/08/17 | 12/31/16 | 424B4 | |
12/21/17 | 09/30/16 | 6-K | |
11/08/17 | 06/30/16 | 424B4 |